View ValuationPro Medicus 향후 성장Future 기준 점검 2/6Pro Medicus (는) 각각 연간 1.5% 및 16.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 1.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 39.2% 로 예상됩니다.핵심 정보1.5%이익 성장률1.50%EPS 성장률Healthcare Services 이익 성장20.1%매출 성장률16.7%향후 자기자본이익률39.16%애널리스트 커버리지Good마지막 업데이트22 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • 2hInvestor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €96.22, the stock trades at a forward P/E ratio of 82x. Average forward P/E is 13x in the Healthcare Services industry in Europe. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €42.53 per share.공고 • Jul 16Pro Medicus Limited to Report Fiscal Year 2026 Results on Aug 18, 2026Pro Medicus Limited announced that they will report fiscal year 2026 results on Aug 18, 2026공고 • Jul 08Pro Medicus Limited Announces Appointment of Garry Sherriff to Head of Investor Relations, Effective July 20, 2026Pro Medicus Limited announced the appointment of Garry Sherriff to the role of Head of Investor Relations, effective July 20, 2026. Garry is a senior financial markets executive with over 20 years’ experience spanning equity research, investment banking, corporate finance, strategy, operations and management. During this time, he has developed deep institutional investor relationships across the Australian and overseas markets. In his previous roles as Head of Australian Equities Research & Lead Technology Analyst for the Royal Bank of Canada, and as Head of Australian Emerging Companies Equity Research for Moelis & Company (now MA Financial), Garry established a proven track record covering Pro Medicus and the broader ASX technology sector.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 34%After last week's 34% share price gain to €101, the stock trades at a forward P/E ratio of 78x. Average forward P/E is 15x in the Healthcare Services industry in Europe. Total returns to shareholders of 166% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €41.81 per share.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Feb 12Pro Medicus Limited Announces Interim Dividend for the six months ended December 31, 2025, Payable on March 20, 2026Pro Medicus Limited announced Interim dividend for the six months ended December 31, 2025 . The distribution will be paid on PME – Ordinary Fully Paid securities. This is a new announcement dated 12 February 2026. The distribution amount is AUD 0.32000000 per security. The ex-date is 26 February 2026, the record date is 27 February 2026, and the payment date is 20 March 2026.공고 • Jan 19Pro Medicus Limited to Report First Half, 2026 Results on Feb 12, 2026Pro Medicus Limited announced that they will report first half, 2026 results on Feb 12, 2026공고 • Sep 24Pro Medicus Limited, Annual General Meeting, Nov 24, 2025Pro Medicus Limited, Annual General Meeting, Nov 24, 2025. Location: leonda by the yarra, 2 wallen road, hawthorn, vic 3122, Australia공고 • Jul 07Pro Medicus Limited to Report Fiscal Year 2025 Results on Aug 14, 2025Pro Medicus Limited announced that they will report fiscal year 2025 results on Aug 14, 2025공고 • Feb 13Pro Medicus Limited Declares Interim Franked Dividend for the Six Months Ended December 31, 2024, Payable on March 21, 2025The Board of Pro Medicus Limited is of the view that there are sufficient cash reserves to fund the anticipated growth of the business from internal sources. Consistent with the Company's dividend policy, the company declared fully franked interim dividend for the six months ended December 31, 2024 is AUD 0.25000000 per share amounting to AUD 26,125,000, payable on 21 March 2025 against AUD 0.18000000 per share in 2024. Record date is on February 28, 2025. Ex-date is on February 27, 2025.공고 • Jan 21Pro Medicus Limited to Report First Half, 2025 Results on Feb 12, 2025Pro Medicus Limited announced that they will report first half, 2025 results on Feb 12, 2025Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Oct 08Pro Medicus Limited, Annual General Meeting, Nov 25, 2024Pro Medicus Limited, Annual General Meeting, Nov 25, 2024. Location: at leonda by the yarra, 2 wallen road, hawthorn, vic 3122., AustraliaDeclared Dividend • Aug 16Final dividend of AU$0.22 announcedShareholders will receive a dividend of AU$0.22. Ex-date: 4th September 2024 Payment date: 26th September 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 50%. Cash payout ratio: 61%.New Risk • Aug 15New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Reported Earnings • Aug 14Full year 2024 earnings released: EPS: AU$0.79 (vs AU$0.58 in FY 2023)Full year 2024 results: EPS: AU$0.79 (up from AU$0.58 in FY 2023). Revenue: AU$166.3m (up 33% from FY 2023). Net income: AU$82.8m (up 37% from FY 2023). Profit margin: 50% (up from 49% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.공고 • Jul 12Pro Medicus Limited to Report Fiscal Year 2024 Results on Aug 14, 2024Pro Medicus Limited announced that they will report fiscal year 2024 results on Aug 14, 2024Upcoming Dividend • Feb 22Upcoming dividend of AU$0.18 per shareEligible shareholders must have bought the stock before 29 February 2024. Payment date: 22 March 2024. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (5.3%). Lower than average of industry peers (1.4%).Declared Dividend • Feb 18First half dividend of AU$0.18 announcedShareholders will receive a dividend of AU$0.18. Ex-date: 29th February 2024 Payment date: 22nd March 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 52%. Cash payout ratio: 58%.Reported Earnings • Feb 16First half 2024 earnings released: EPS: AU$0.35 (vs AU$0.26 in 1H 2023)First half 2024 results: EPS: AU$0.35 (up from AU$0.26 in 1H 2023). Revenue: AU$74.1m (up 30% from 1H 2023). Net income: AU$36.3m (up 33% from 1H 2023). Profit margin: 49% (up from 48% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.공고 • Jan 16Pro Medicus Limited to Report First Half, 2024 Results on Feb 15, 2024Pro Medicus Limited announced that they will report first half, 2024 results on Feb 15, 2024Recent Insider Transactions • Nov 30Co-Founder recently sold €53m worth of stockOn the 21st of November, Anthony Hall sold around 1m shares on-market at roughly €52.86 per share. This transaction amounted to 3.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anthony has been a net seller over the last 12 months, reducing personal holdings by €92m.New Risk • Nov 26New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €53m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Significant insider selling over the past 3 months (€53m sold).공고 • Oct 10Pro Medicus Limited, Annual General Meeting, Nov 20, 2023Pro Medicus Limited, Annual General Meeting, Nov 20, 2023, at 10:00 AUS Eastern Standard Time. Location: The Yarra, 2 Wallen Road Leonda Hawthorn AustraliaBoard Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Aug 30Upcoming dividend of AU$0.17 per share at 0.5% yieldEligible shareholders must have bought the stock before 06 September 2023. Payment date: 28 September 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.3%).New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 32% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.Reported Earnings • Aug 15Full year 2023 earnings released: EPS: AU$0.58 (vs AU$0.43 in FY 2022)Full year 2023 results: EPS: AU$0.58 (up from AU$0.43 in FY 2022). Revenue: AU$127.3m (up 35% from FY 2022). Net income: AU$60.6m (up 37% from FY 2022). Profit margin: 48% (in line with FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.공고 • Jul 22Pro Medicus Limited to Report Fiscal Year 2023 Final Results on Aug 15, 2023Pro Medicus Limited announced that they will report fiscal year 2023 final results on Aug 15, 2023Recent Insider Transactions • Mar 15Chairman recently sold €1.9m worth of stockOn the 13th of March, Peter Kempen sold around 50k shares on-market at roughly €38.19 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.Upcoming Dividend • Feb 23Upcoming dividend of AU$0.13 per share at 0.4% yieldEligible shareholders must have bought the stock before 02 March 2023. Payment date: 24 March 2023. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.3%).Reported Earnings • Feb 16First half 2023 earnings released: EPS: AU$0.26 (vs AU$0.20 in 1H 2022)First half 2023 results: EPS: AU$0.26 (up from AU$0.20 in 1H 2022). Revenue: AU$56.9m (up 28% from 1H 2022). Net income: AU$27.2m (up 32% from 1H 2022). Profit margin: 48% (up from 47% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.공고 • Feb 15Pro Medicus Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on March 24, 2023Pro Medicus Limited announced dividend for the six months ended December 31, 2022 of AUD 0.13000000 per share. Ex-date is March 2, 2023. Record date is March 3, 2023. Payment date is March 24, 2023.공고 • Jan 24Pro Medicus Limited to Report First Half, 2023 Results on Feb 15, 2023Pro Medicus Limited announced that they will report first half, 2023 results on Feb 15, 2023Upcoming Dividend • Sep 01Upcoming dividend of AU$0.12 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.4%).Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.43 (vs AU$0.30 in FY 2021)Full year 2022 results: EPS: AU$0.43 (up from AU$0.30 in FY 2021). Revenue: AU$94.1m (up 38% from FY 2021). Net income: AU$44.4m (up 44% from FY 2021). Profit margin: 47% (up from 45% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 24%, compared to a 16% growth forecast for the Healthcare Services industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 26% per year.Upcoming Dividend • Feb 24Upcoming dividend of AU$0.10 per shareEligible shareholders must have bought the stock before 03 March 2022. Payment date: 25 March 2022. Payout ratio is a comfortable 49% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (1.2%).Reported Earnings • Feb 17First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: EPS: AU$0.20 (up from AU$0.13 in 1H 2021). Revenue: AU$44.3m (up 40% from 1H 2021). Net income: AU$20.7m (up 53% from 1H 2021). Profit margin: 47% (up from 43% in 1H 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 28%, compared to a 44% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Sep 02Upcoming dividend of AU$0.08 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 01 October 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.9%).Reported Earnings • Aug 18Full year 2021 earnings released: EPS AU$0.30 (vs AU$0.22 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$68.1m (up 20% from FY 2020). Net income: AU$30.9m (up 34% from FY 2020). Profit margin: 45% (up from 41% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Mar 03New 90-day high: €30.54The company is up 69% from its price of €18.12 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.97 per share.Upcoming Dividend • Feb 25Upcoming Dividend of AU$0.07 Per ShareWill be paid on the 19th of March to those who are registered shareholders by the 4th of March. The trailing yield of 0.3% is below the top quartile of German dividend payers (3.4%), and is lower than industry peers (1.0%).Recent Insider Transactions • Feb 23Co-Founder recently sold €30m worth of stockOn the 18th of February, Anthony Hall sold around 1m shares on-market at roughly €29.50 per share. This was the largest sale by an insider in the last 3 months. Anthony has been a seller over the last 12 months, reducing personal holdings by €29m.Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 37%, compared to a 21% growth forecast for the Healthcare Services industry in Germany.Reported Earnings • Feb 18First half 2021 earnings released: EPS AU$0.13 (vs AU$0.12 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$31.6m (up 7.8% from 1H 2020). Net income: AU$13.5m (up 12% from 1H 2020). Profit margin: 43% (up from 41% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Feb 08New 90-day high: €27.85The company is up 40% from its price of €19.94 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.53 per share.Is New 90 Day High Low • Jan 14New 90-day high: €23.11The company is up 29% from its price of €17.91 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.71 per share.Is New 90 Day High Low • Dec 19New 90-day high: €20.91The company is up 37% from its price of €15.25 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.36 per share.Is New 90 Day High Low • Nov 05New 90-day high: €20.58The company is up 45% from its price of €14.15 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.26 per share.Is New 90 Day High Low • Oct 08New 90-day high: €17.07The company is up 11% from its price of €15.40 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.05 per share.이익 및 매출 성장 예측DB:PMC - 애널리스트 향후 추정치 및 과거 재무 데이터 (AUD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/202949228525628056/30/2028414233216229146/30/2027335187172182146/30/20262622411321351412/31/2025241235120128N/A9/30/2025227175112120N/A6/30/2025213115104111N/A3/31/202519910799107N/A12/31/20241859895102N/A9/30/2024173918592N/A6/30/2024162837582N/A3/31/2024152767077N/A12/31/2023142706571N/A9/30/2023134656067N/A6/30/2023125615663N/A3/31/2023115565159N/A12/31/2022106514755N/A9/30/2022100485058N/A6/30/202293445362N/A3/31/202287414755N/A12/31/202181384149N/A9/30/202174343644N/A6/30/202168313139N/A3/31/202164282736N/A12/31/202059252432N/A9/30/202058242432N/A6/30/202057232431N/A3/31/202055232533N/A12/31/201954222734N/A9/30/20195221N/A30N/A6/30/20195019N/A25N/A3/31/20194717N/AN/AN/A12/31/20184316N/A14N/A9/30/20183913N/A14N/A6/30/20183410N/A14N/A3/31/2018339N/AN/AN/A12/31/2017328N/A15N/A9/30/2017329N/A15N/A6/30/2017329N/A15N/A3/31/2017309N/A13N/A12/31/2016288N/A12N/A9/30/2016287N/A11N/A6/30/2016286N/A11N/A3/31/2016255N/A9N/A12/31/2015235N/A8N/A9/30/2015204N/A6N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: PMC 의 연간 예상 수익 증가율(1.5%)이 saving rate(1.9%) 미만입니다.수익 vs 시장: PMC 의 연간 수익(1.5%)이 German 시장(15.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: PMC 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: PMC 의 수익(연간 16.7%)이 German 시장(연간 6.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: PMC 의 수익(연간 16.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: PMC의 자본 수익률은 3년 후 39.2%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 01:52종가2026/07/23 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pro Medicus Limited는 27명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Josh KannourakisBarrenjoey Markets Pty LimitedJohn HesterBell PotterMadeleine WilliamsCanaccord Genuity24명의 분석가 더 보기
Valuation Update With 7 Day Price Move • 2hInvestor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €96.22, the stock trades at a forward P/E ratio of 82x. Average forward P/E is 13x in the Healthcare Services industry in Europe. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €42.53 per share.
공고 • Jul 16Pro Medicus Limited to Report Fiscal Year 2026 Results on Aug 18, 2026Pro Medicus Limited announced that they will report fiscal year 2026 results on Aug 18, 2026
공고 • Jul 08Pro Medicus Limited Announces Appointment of Garry Sherriff to Head of Investor Relations, Effective July 20, 2026Pro Medicus Limited announced the appointment of Garry Sherriff to the role of Head of Investor Relations, effective July 20, 2026. Garry is a senior financial markets executive with over 20 years’ experience spanning equity research, investment banking, corporate finance, strategy, operations and management. During this time, he has developed deep institutional investor relationships across the Australian and overseas markets. In his previous roles as Head of Australian Equities Research & Lead Technology Analyst for the Royal Bank of Canada, and as Head of Australian Emerging Companies Equity Research for Moelis & Company (now MA Financial), Garry established a proven track record covering Pro Medicus and the broader ASX technology sector.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment improves as stock rises 34%After last week's 34% share price gain to €101, the stock trades at a forward P/E ratio of 78x. Average forward P/E is 15x in the Healthcare Services industry in Europe. Total returns to shareholders of 166% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €41.81 per share.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Feb 12Pro Medicus Limited Announces Interim Dividend for the six months ended December 31, 2025, Payable on March 20, 2026Pro Medicus Limited announced Interim dividend for the six months ended December 31, 2025 . The distribution will be paid on PME – Ordinary Fully Paid securities. This is a new announcement dated 12 February 2026. The distribution amount is AUD 0.32000000 per security. The ex-date is 26 February 2026, the record date is 27 February 2026, and the payment date is 20 March 2026.
공고 • Jan 19Pro Medicus Limited to Report First Half, 2026 Results on Feb 12, 2026Pro Medicus Limited announced that they will report first half, 2026 results on Feb 12, 2026
공고 • Sep 24Pro Medicus Limited, Annual General Meeting, Nov 24, 2025Pro Medicus Limited, Annual General Meeting, Nov 24, 2025. Location: leonda by the yarra, 2 wallen road, hawthorn, vic 3122, Australia
공고 • Jul 07Pro Medicus Limited to Report Fiscal Year 2025 Results on Aug 14, 2025Pro Medicus Limited announced that they will report fiscal year 2025 results on Aug 14, 2025
공고 • Feb 13Pro Medicus Limited Declares Interim Franked Dividend for the Six Months Ended December 31, 2024, Payable on March 21, 2025The Board of Pro Medicus Limited is of the view that there are sufficient cash reserves to fund the anticipated growth of the business from internal sources. Consistent with the Company's dividend policy, the company declared fully franked interim dividend for the six months ended December 31, 2024 is AUD 0.25000000 per share amounting to AUD 26,125,000, payable on 21 March 2025 against AUD 0.18000000 per share in 2024. Record date is on February 28, 2025. Ex-date is on February 27, 2025.
공고 • Jan 21Pro Medicus Limited to Report First Half, 2025 Results on Feb 12, 2025Pro Medicus Limited announced that they will report first half, 2025 results on Feb 12, 2025
Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Oct 08Pro Medicus Limited, Annual General Meeting, Nov 25, 2024Pro Medicus Limited, Annual General Meeting, Nov 25, 2024. Location: at leonda by the yarra, 2 wallen road, hawthorn, vic 3122., Australia
Declared Dividend • Aug 16Final dividend of AU$0.22 announcedShareholders will receive a dividend of AU$0.22. Ex-date: 4th September 2024 Payment date: 26th September 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 50%. Cash payout ratio: 61%.
New Risk • Aug 15New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 30% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Reported Earnings • Aug 14Full year 2024 earnings released: EPS: AU$0.79 (vs AU$0.58 in FY 2023)Full year 2024 results: EPS: AU$0.79 (up from AU$0.58 in FY 2023). Revenue: AU$166.3m (up 33% from FY 2023). Net income: AU$82.8m (up 37% from FY 2023). Profit margin: 50% (up from 49% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
공고 • Jul 12Pro Medicus Limited to Report Fiscal Year 2024 Results on Aug 14, 2024Pro Medicus Limited announced that they will report fiscal year 2024 results on Aug 14, 2024
Upcoming Dividend • Feb 22Upcoming dividend of AU$0.18 per shareEligible shareholders must have bought the stock before 29 February 2024. Payment date: 22 March 2024. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (5.3%). Lower than average of industry peers (1.4%).
Declared Dividend • Feb 18First half dividend of AU$0.18 announcedShareholders will receive a dividend of AU$0.18. Ex-date: 29th February 2024 Payment date: 22nd March 2024 Dividend yield will be 0.5%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 52%. Cash payout ratio: 58%.
Reported Earnings • Feb 16First half 2024 earnings released: EPS: AU$0.35 (vs AU$0.26 in 1H 2023)First half 2024 results: EPS: AU$0.35 (up from AU$0.26 in 1H 2023). Revenue: AU$74.1m (up 30% from 1H 2023). Net income: AU$36.3m (up 33% from 1H 2023). Profit margin: 49% (up from 48% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
공고 • Jan 16Pro Medicus Limited to Report First Half, 2024 Results on Feb 15, 2024Pro Medicus Limited announced that they will report first half, 2024 results on Feb 15, 2024
Recent Insider Transactions • Nov 30Co-Founder recently sold €53m worth of stockOn the 21st of November, Anthony Hall sold around 1m shares on-market at roughly €52.86 per share. This transaction amounted to 3.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Anthony has been a net seller over the last 12 months, reducing personal holdings by €92m.
New Risk • Nov 26New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €53m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Significant insider selling over the past 3 months (€53m sold).
공고 • Oct 10Pro Medicus Limited, Annual General Meeting, Nov 20, 2023Pro Medicus Limited, Annual General Meeting, Nov 20, 2023, at 10:00 AUS Eastern Standard Time. Location: The Yarra, 2 Wallen Road Leonda Hawthorn Australia
Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Alice Joans Williams was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Aug 30Upcoming dividend of AU$0.17 per share at 0.5% yieldEligible shareholders must have bought the stock before 06 September 2023. Payment date: 28 September 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.3%).
New Risk • Aug 17New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 32% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. This is currently the only risk that has been identified for the company.
Reported Earnings • Aug 15Full year 2023 earnings released: EPS: AU$0.58 (vs AU$0.43 in FY 2022)Full year 2023 results: EPS: AU$0.58 (up from AU$0.43 in FY 2022). Revenue: AU$127.3m (up 35% from FY 2022). Net income: AU$60.6m (up 37% from FY 2022). Profit margin: 48% (in line with FY 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Jul 22Pro Medicus Limited to Report Fiscal Year 2023 Final Results on Aug 15, 2023Pro Medicus Limited announced that they will report fiscal year 2023 final results on Aug 15, 2023
Recent Insider Transactions • Mar 15Chairman recently sold €1.9m worth of stockOn the 13th of March, Peter Kempen sold around 50k shares on-market at roughly €38.19 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
Upcoming Dividend • Feb 23Upcoming dividend of AU$0.13 per share at 0.4% yieldEligible shareholders must have bought the stock before 02 March 2023. Payment date: 24 March 2023. Payout ratio is a comfortable 51% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.3%).
Reported Earnings • Feb 16First half 2023 earnings released: EPS: AU$0.26 (vs AU$0.20 in 1H 2022)First half 2023 results: EPS: AU$0.26 (up from AU$0.20 in 1H 2022). Revenue: AU$56.9m (up 28% from 1H 2022). Net income: AU$27.2m (up 32% from 1H 2022). Profit margin: 48% (up from 47% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth.
공고 • Feb 15Pro Medicus Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on March 24, 2023Pro Medicus Limited announced dividend for the six months ended December 31, 2022 of AUD 0.13000000 per share. Ex-date is March 2, 2023. Record date is March 3, 2023. Payment date is March 24, 2023.
공고 • Jan 24Pro Medicus Limited to Report First Half, 2023 Results on Feb 15, 2023Pro Medicus Limited announced that they will report first half, 2023 results on Feb 15, 2023
Upcoming Dividend • Sep 01Upcoming dividend of AU$0.12 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.4%).
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.43 (vs AU$0.30 in FY 2021)Full year 2022 results: EPS: AU$0.43 (up from AU$0.30 in FY 2021). Revenue: AU$94.1m (up 38% from FY 2021). Net income: AU$44.4m (up 44% from FY 2021). Profit margin: 47% (up from 45% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 24%, compared to a 16% growth forecast for the Healthcare Services industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 26% per year.
Upcoming Dividend • Feb 24Upcoming dividend of AU$0.10 per shareEligible shareholders must have bought the stock before 03 March 2022. Payment date: 25 March 2022. Payout ratio is a comfortable 49% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (1.2%).
Reported Earnings • Feb 17First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: EPS: AU$0.20 (up from AU$0.13 in 1H 2021). Revenue: AU$44.3m (up 40% from 1H 2021). Net income: AU$20.7m (up 53% from 1H 2021). Profit margin: 47% (up from 43% in 1H 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Over the next year, revenue is forecast to grow 28%, compared to a 44% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Sep 02Upcoming dividend of AU$0.08 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 01 October 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.9%).
Reported Earnings • Aug 18Full year 2021 earnings released: EPS AU$0.30 (vs AU$0.22 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$68.1m (up 20% from FY 2020). Net income: AU$30.9m (up 34% from FY 2020). Profit margin: 45% (up from 41% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Mar 03New 90-day high: €30.54The company is up 69% from its price of €18.12 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.97 per share.
Upcoming Dividend • Feb 25Upcoming Dividend of AU$0.07 Per ShareWill be paid on the 19th of March to those who are registered shareholders by the 4th of March. The trailing yield of 0.3% is below the top quartile of German dividend payers (3.4%), and is lower than industry peers (1.0%).
Recent Insider Transactions • Feb 23Co-Founder recently sold €30m worth of stockOn the 18th of February, Anthony Hall sold around 1m shares on-market at roughly €29.50 per share. This was the largest sale by an insider in the last 3 months. Anthony has been a seller over the last 12 months, reducing personal holdings by €29m.
Analyst Estimate Surprise Post Earnings • Feb 18Revenue misses expectationsRevenue missed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 37%, compared to a 21% growth forecast for the Healthcare Services industry in Germany.
Reported Earnings • Feb 18First half 2021 earnings released: EPS AU$0.13 (vs AU$0.12 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$31.6m (up 7.8% from 1H 2020). Net income: AU$13.5m (up 12% from 1H 2020). Profit margin: 43% (up from 41% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Feb 08New 90-day high: €27.85The company is up 40% from its price of €19.94 on 10 November 2020. The German market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €12.53 per share.
Is New 90 Day High Low • Jan 14New 90-day high: €23.11The company is up 29% from its price of €17.91 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.71 per share.
Is New 90 Day High Low • Dec 19New 90-day high: €20.91The company is up 37% from its price of €15.25 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €13.36 per share.
Is New 90 Day High Low • Nov 05New 90-day high: €20.58The company is up 45% from its price of €14.15 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.26 per share.
Is New 90 Day High Low • Oct 08New 90-day high: €17.07The company is up 11% from its price of €15.40 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.05 per share.